samedan logo
 
 
spacer
home > epc > our clients
OUR CLIENTS

The magazine’s readership is 10,500, targeted directly at strategic decision-makers within pharmaceutical companies and their contract partners across Europe, North America and the rest of the world. Combining editorial integrity with a broad spectrum of topic areas, the magazine has proved an effective advertising medium for organisations wishing to target this dynamic market.

Advertisers in the last issue of EPC were:

Almac Group Ltd

Alternatives Technologie Pharma Inc

Analytical Biochemical Laboratory BV

Azopharma Product Development Group Inc

Clinical Data Interchange Standards Consortium, Inc (CDISC)

CROM srl

CRS Clinical Research Services Andernach GmbH

Dila Medical Laboratory

Dr Oestreich+Partner GmbH

ERT

Faubel & Co Nachfolger GmbH

FOCUS Clinical Drug Development GmbH

Harlan Laboratories, Inc

Informa Life Sciences

INTERLAB central lab services - worldwide GmbH

KCR SA

Kendle

LORENZ Life Sciences Group

Marken

MDS Pharma Services

Medidata Solutions Worldwide

MediLingua BV

MSOURCE Medical Development

NOTOX BV

Patheon

Pharm-Olam International

Quest Diagnostics Incorporated

SCA Cool Logistics

S-cubed

Simbec Research Limited

SMi Group Ltd

Synergy Research Group

The Institute of Clinical Research

UBM International Media

Vitalograph

Woodley Equipment Company Ltd

XML4Pharma

 

spacer
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
March, June,
September and December
 
Industry Events

Sample Management Benchmarking Symposium

15 September 2010, Griesheim, Germany

BioStorage Technologies Inc, a global leader in sample management, cold chain logistics and biomaterial storage for the pharmaceutical and biotechnology industries, is hosting a global sample management benchmarking symposium in Griesheim, Germany for biobanking and biospecimen professionals from the pharmaceutical, biotechnology and academic industries.
More info >>

 
News and Press Releases

Glycotope GMBH

Berlin, Germany – August 4, 2010 Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX (GT-MAB 5.2-GEX) for the treatment of various solid cancers.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement